|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to residues 496-511 of human BACE2.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for this product is human heart tissue lysate.
Accumulation of the amyloid-b (Ab) plaque in the cerebral cortex is a critical event in the pathogenesis Alzheimer's disease. Ab peptide is generated by proteolytic cleavage of the b-amyloid protein precursor(APP) at b- and g-sites by two proteases. APP is first cleaved by b-secretase, producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for g-secretase to generate the 4 kDa amyloid-b peptide, which is deposited in the brains of all sufferers of Alzheimer's disease. The long-sought b-secretase was recently identified by several groups independently and designated beta-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2) (1-4). bACE/Asp2 is a novel transmembrane aspartic protease and colocalizes with APP.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.